NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with known known microsatellite-instability high (MSI- H) or deficient in mismatch repair (dMMR) disease are required to have received prior PD 1/PD-L1 therapy
Exclusions: Patients with active or untreated known CNS metastases and/or leptomeningeal disease

Comments are closed.

Up ↑